HER2 Support Group Forums - View Single Post - Valproic acid against er+ cancer (from top 5 list)

Rich66 · 11-18-2008, 01:00 PM

1: Cancer Lett. 2008 Feb 8;259(2):156-64. Epub 2007 Nov 19. Links: Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.

Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G.
Oncological Endocrinology, ASO San Giovanni Battista, Via Genova 3, 10126 Turin, Italy.
Treatment efficacy of breast cancer can be impaired by cell resistance. The aim of the study was to investigate the anti-tumour effects of valproic acid (VPA), the only clinically available histone deacetylase inhibitor, on both estrogen-sensitive and -insensitive breast cancer cells. VPA, at a concentration lacking severe adverse effects in human, reduces cell viability in estrogen-sensitive cell lines, inducing p21 expression and impairing cell cycle. In ZR-75-1, cell cycle is selectively arrested in G1, whereas MCF-7 cells massively accumulated in sub-G1. Actually, in MCF-7 cells, VPA induces apoptosis, down-regulates Bcl-2 and up-regulates Bak expression. In conclusion, VPA is a powerful antiproliferative agent in estrogen-sensitive breast cancer cells, making this drug of clinical interest as a new approach to treat breast cancer.
PMID: 18006146 [PubMed - indexed for MEDLINE

11-18-2008, 01:00 PM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Valproic acid against er+ cancer (from top 5 list) 1: Cancer Lett. 2008 Feb 8;259(2):156-64. Epub 2007 Nov 19. Links Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G. Oncological Endocrinology, ASO San Giovanni Battista, Via Genova 3, 10126 Turin, Italy. Treatment efficacy of breast cancer can be impaired by cell resistance. The aim of the study was to investigate the anti-tumour effects of valproic acid (VPA), the only clinically available histone deacetylase inhibitor, on both estrogen-sensitive and -insensitive breast cancer cells. VPA, at a concentration lacking severe adverse effects in human, reduces cell viability in estrogen-sensitive cell lines, inducing p21 expression and impairing cell cycle. In ZR-75-1, cell cycle is selectively arrested in G1, whereas MCF-7 cells massively accumulated in sub-G1. Actually, in MCF-7 cells, VPA induces apoptosis, down-regulates Bcl-2 and up-regulates Bak expression. In conclusion, VPA is a powerful antiproliferative agent in estrogen-sensitive breast cancer cells, making this drug of clinical interest as a new approach to treat breast cancer. PMID: 18006146 [PubMed - indexed for MEDLINE __________________ Mom's treatment history (link)